Cytomegalovirus infection (CMV)

Cytomegalovirus infection is an infection caused by a type of herpes virus, human herpesvirus type 5 (CMV), belonging to the Betaherpesviridae family. It is part of the diseases included in the TORCH panel. The transmission of the virus is through contact with urine, saliva, mucus from the cervix, semen, feces and breast milk of the infected person. It can also be passed from mother to child during pregnancy (congenital CMV) or childbirth (perinatal CMV). It can also be the case of transmission through blood transfusion or organ transplant. The symptoms depend on the type of person infected, being more likely to be experienced by newborns and people with a weakened immune system. In the case of congenital CMV, the most common are premature birth, low birth weight, jaundice, liver and skin problems, microencephaly, large spleen, pneumonia, and seizures. In the case of perinatal CMV, the vast majority of cases are asymptomatic, but in premature babies a serious and even fatal infection can occur. People with weakened immune systems may have problems with organs such as the eyes, lungs, liver, esophagus, stomach, intestines, and brain. Most healthy people infected with CMV show no symptoms. In the case of having symptoms, they are very similar to those of infectious mononucleosis: fatigue, fever and muscle and throat pain. The most common treatment is the use of antivirals to slow down the reproduction of the virus, but not eliminate it. As prevention it is recommended to maintain good hygiene and take antivirals to prevent the disease in case of weakened immunity. The diagnosis of CMV is made by testing blood and other body fluids, as well as tissue samples.

Cytomegalovirus infection is a widespread worldwide infection, there is no cure, and, once contracted, the virus remains in the body for life. The vast majority of infected people do not know they are infected, as it rarely causes problems in healthy people. For pregnant women and people with a weakened immune system, it is a cause for concern, since it can be fatal. It is estimated that 60%-90% of adults have a CMV infection. The prevalence increases with age, with people of low socioeconomic levels tending to have a lower prevalence. CMV is the virus most frequently transmitted to the fetus. It is estimated that it affects 0.2-1% of newborns worldwide. Only about 10% of newborns with congenital infection are symptomatic at birth. The rest appear healthy at birth. It's months, or even years, when they begin to show symptoms, such as hearing loss and developmental delay.

Human infectious disease.

At Rekom Biotech, we desing and manufacture IVD reagents for diagnosis of Cytomegalovirus infection (CMV). If you do not find what you are looking for, you can request our custom-made recombinant proteins/antibodies service. Do not hesitate to contact us!

or

BACT TO LIST OF INFECTIOUS DISEASES

Recombinant proteins

DISEASE/MICROORGANISM NAME CAT NUMBER DESCRIPTION DETAILS

Cytomegalovirus infection (CMV)

ChimCMV1
RAG0109 (chimera) Top product (Satisfaction guarantee)
RAG0109BIOT (biotinylated, chimera)
Multi-epitope recombinant chimeric antigen for CMV
ChimCMV2
RAG0110 (chimera)
RAG0110BIOT (biotinylated, chimera)
Multi-epitope recombinant chimeric antigen for CMV
ChimCMV3
RAG0018 (chimera) New
Multi-epitope recombinant chimeric antigen for CMV
pp150
RAG0059 Top product (Satisfaction guarantee) New
RAG0091 Top product (Satisfaction guarantee)
Viral matrix phosphoprotein
pp28
RAG0004 New
Phosphoprotein
pp52
RAG0090 Top product (Satisfaction guarantee)
RAG0090BIOT (biotinylated)
DNA polymerase processivity subunit
pp65
RAG0016 Top product (Satisfaction guarantee)
Viral tegument phosphoprotein

Polyclonal antibodies

DISEASE/MICROORGANISM NAME CAT NUMBER DESCRIPTION DETAILS

Cytomegalovirus infection (CMV)

Anti-pp150
PAB0002
Polyclonal antibody against pp150 for Cytomegalovirus
Anti-pp52
PAB0001
Polyclonal antibody against pp52 for Cytomegalovirus
Anti-pp65
PAB0003
Polyclonal antibody against pp65 for Cytomegalovirus

Pipeline

Recombinant proteins

Design

Protein design from scratch, always trying to improve its antigenic capacity.

Verification

Search for the best DNA construction according to the design phase.

Expression system

Selection of the best expression system for the protein.

USP/DSP process tuning

Process adjustments to achieve an optimal seed, and the process to isolate our protein from the obtained seed.

Validation

Validation and full quality control.

p130 for Cytomegalovirus infection (CMV) (human)
USP/DSP process tuning